ISIS 2503 in Treating Patients With Metastatic and/or Locally Recurrent Colorectal Cancer
Status:
Terminated
Trial end date:
2000-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: ISIS 2503 may kill cancer cells by inhibiting a gene that promotes the development
and growth of cancer.
PURPOSE: Phase II trial to study the effectiveness of ISIS 2503 in treating patients who have
metastatic and/or locally recurrent colorectal cancer.